Regeneron Pharmaceuticals, Inc. $REGN Position Lifted by Parcion Private Wealth LLC

Parcion Private Wealth LLC grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 55.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 1,589 shares of the biopharmaceutical company’s stock after buying an additional 567 shares during the quarter. Parcion Private Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $1,205,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. Soltis Investment Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 49.4% during the 3rd quarter. Soltis Investment Advisors LLC now owns 1,210 shares of the biopharmaceutical company’s stock valued at $917,000 after buying an additional 400 shares in the last quarter. Choreo LLC boosted its stake in Regeneron Pharmaceuticals by 4.5% in the third quarter. Choreo LLC now owns 5,763 shares of the biopharmaceutical company’s stock worth $4,370,000 after buying an additional 249 shares in the last quarter. Willner & Heller LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $210,000. Values Added Financial LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $244,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 12.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,862 shares of the biopharmaceutical company’s stock worth $16,408,000 after acquiring an additional 2,364 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Leerink Partners boosted their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective for the company in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $850.83.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $927.89 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a market cap of $95.54 billion, a PE ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.16. The business has a 50 day moving average of $793.30 and a 200 day moving average of $738.05. Regeneron Pharmaceuticals, Inc. has a 52 week low of $591.52 and a 52 week high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period last year, the company posted $11.83 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares of the company’s stock, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 4,147 shares of the firm’s stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This represents a 7.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock valued at $6,506,845 in the last three months. Company insiders own 6.97% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.